Back to News
Market Impact: 0.2
Orchestra BioMed Receives $6.1 Million Milestone Payment From Vivasure Acquisition By Haemonetics
Source: Nasdaq
Healthcare & BiotechM&A & RestructuringCompany Fundamentals
Orchestra BioMed received a $6.1 million milestone payment triggered by Haemonetics' acquisition of Vivasure Medical. The payment provides a positive, though modest, financial benefit to Orchestra BioMed and reflects value realization from its strategic-partnership technology model.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
HAE0.12
OBIO0.58
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Binance’s $6.3 Billion Cyber Heist Shows Crypto Vulnerabilities
- Big Oil Scores $56 Billion Windfall on Spiking Fuel Prices
- Chevron speeds ahead in Venezuela while Exxon urges caution with a ‘little pinch of salt’
- Backbone of a beast – charting Nvidia's rise to networking titan
- OpenAI raises just $11bn of $30bn target as AI investor appetite cools
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- How to Use AI for an Initiating Coverage Report
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)